|
Carvolix is a French medical technology company at the clinical and pre-commercial stage, founded in 2018 by Truffle Capital. The company develops AI-driven robotic platforms, advanced imaging software, and implantable devices for the treatment of structural heart diseases and ischemic stroke. Its portfolio includes Tavipilot, an AI-based software solution for guiding transcatheter aortic valve implantation procedures that has received FDA clearance, and Tavipilot Robot, a robotic system designed to automate steps in TAVI procedures. Carvolix also develops Artus, an artificial urinary sphincter for severe incontinence, and Kalios, a mitral annuloplasty ring for minimally invasive valve repair. The group holds Epygon, Kardiozis, Kephalios, and MyoPowers, and acquired Caranx Medical and Artedrone in early 2026. Artedrone is a robotic platform for neurovascular interventions, specifically for thrombectomy in ischemic stroke. The company targets interventional cardiologists and neurologists globally, with a focus on expanding access to complex procedures through supervised autonomy and precision robotics. Carvolix was formerly known as Affluent Medical. Summarised from the company's own disclosures, fiscal year ended Apr 2026 |
Industry Medical Devices | Homepage carvolix.eu |
| Sector Healthcare | IR page carvolix.eu/investors | |
|
Tags
interventional cardiology, structural heart disease, ischemic stroke, robotic surgery, artificial intelligence, medical imaging, transcatheter aortic valve implantation, mitral valve repair, urinary incontinence, thrombectomy, Tavipilot, Tavipilot Robot, Artus, Kalios, Mitrapilot, Artedrone, Epygon, Kardiozis, Kephalios, MyoPowers, Caranx Medical, Epygon Italie SRL, Medev Europa SRL, Shanghai Epygon Medical Technology Co Ltd, Shanghai MyoPowers Medical Technology Co. Ltd
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | — |
| P/E | — |
| P/BV | — |
| P/S | — |
| P/OCF | — |
| P/FCF | — |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | -138.6% |
| ROI | -141.7% |
| ROIC | -100.8% |
| Profit margin | — |
| Growth | |
|---|---|
| Revenue growing | — |
| Profits growing | No |
| Revenue up 3y | — |
| Revenue up 5y | — |
| Quality | |
|---|---|
| Profitable | No |
| Margin expanding | — |
| Buying back stock | No |
| Diluting (TTM) | No |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 0 |
| Quality score | -50.0% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpPrompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.